Evidence map›Paper›PMID 41608630›Full record

ArticleInternational journal of biological sciences2026

Klotho-derived peptide 1 ameliorates hepatic fibrosis induced by αKlotho deficiency and liver injury.

Huishi Tan, Wenshu Huang, Hanying Luo, Wenjian Min, Xiaoyao Zhang, Xiaoli Sun, Enqing Lin, Xue Hong, Peng Yang, Lili Zhou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Huishi TanState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wenshu HuangState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Hanying LuoState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wenjian MinState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Xiaoyao ZhangState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xiaoli SunState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Enqing LinState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xue HongState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Peng YangState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China.
Lili ZhouState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Youhua LiuState Key Laboratory of Multi-organ Injury Prevention and Treatment, National Clinical Research Center for Kidney Disease, Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic fibrosis, driven primarily by hepatic stellate cells (HSCs) activation induced by TGF-β, currently lacks effective therapies. In this study, we demonstrated that deficiency of αKlotho, an extrahepatic antiaging protein, due to genetic ablation in

Indexed as

GlucuronidaseLiver CirrhosisAnimalsHepatic Stellate CellsHumansKlotho ProteinsLiverMaleMiceMice, Inbred C57BLPeptidesSignal TransductionTransforming Growth Factor beta1GlucuronidaseKlotho ProteinsKL protein, humanLeu-Ser-Lys-Leu peptidePeptidesTransforming Growth Factor beta1hepatic stellate cellsKlothoKP1liver fibrosisTGF-βTGF-β receptor 2

Identifiers

PMID41608630
PMCPMC12837819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.